Companies › Shanghai Minwei Biotechnology
4 active drug programs in 9 registered trials: 5 Phase 1, 4 Phase 2; Metabolic and endocrine, Cardiovascular, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MWN109 2 GLP-1 receptor agonist | GLP1R | Phase 2 | Overweight , Obesity; Type 2 Diabetes Mellitus (T2DM); Overweight or Obese; Overweight or Obesity | Nov 2026 |
| MWX203 APOC3 inhibitor | – | Phase 2 | Mixed Dyslipidemia; Healthy Volunteers | Jan 2027 |
| MWX401 Unclear - specific mechanism not stated in registry entry | – | Phase 1 | Essential Hypertension | Dec 2026 |
| MWN105 | – | Phase 1 | Overweight , Obesity | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06859853 | MWN109 2 | Phase 1 | Overweight or Obese | Metabolic and endocrine | Sep 2025 |
| NCT06938269 | MWN109 2 | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Mar 2026 |
| NCT07804797 | MWN109 2 | Phase 2 | Overweight , Obesity | Metabolic and endocrine | Sep 2026 |
| NCT07791537 | MWN109 2 | Phase 2 | Overweight , Obesity | Metabolic and endocrine | Nov 2026 |
| NCT07803835 | MWX401 | Phase 1 | Essential Hypertension | Cardiovascular | Dec 2026 |
| NCT07803809 | MWN105 | Phase 1 | Overweight , Obesity | Metabolic and endocrine | Jan 2027 |
| NCT07799025 | MWX203 | Phase 1 | Healthy Volunteers | Other | Jan 2027 |
| NCT07801820 | MWN109 2 | Phase 2 | Type 2 Diabetes Mellitus (T2DM) | Metabolic and endocrine | Mar 2027 |
| NCT07803822 | MWX203 | Phase 2 | Mixed Dyslipidemia | Cardiovascular | Feb 2028 |
Beijing QL Biopharmaceutical Fujian Shengdi Pharmaceutical Chendu DIAO Pharmaceutical Group Verdiva Bio Dev Sirius Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.